Guidelines for Restarting Rituximab After Pneumocystis jirovecii Pneumonia in Mantle‑Cell Lymphoma

1. Completion of PJP Therapy

• A full 14–21‑day course of high‑dose trimethoprim‑sulfamethoxazole (TMP/SMX) is required before chemotherapy can be resumed. 1
• The patient must be afebrile for at least 48–72 hours and clinically stable before restarting lymphoma treatment. 3

2. Mandatory Secondary Prophylaxis

• All individuals who have successfully been treated for PJP should receive secondary prophylaxis to prevent recurrence. 1
• Preferred prophylactic agents are intermittent oral TMP/SMX or monthly aerosolized pentamidine. 1
• Prophylaxis should be continued throughout the remainder of chemotherapy and may be extended beyond treatment because bendamustine‑rituximab causes prolonged T‑cell suppression. 5

3. Management of Persistent Neutropenia

• Persistent neutropenia alone does not contraindicate resumption of rituximab once the PJP infection is adequately treated. 3
• PJP treatment and secondary prophylaxis must be continued regardless of the neutrophil count. 1

4. Timing and Dosing of Rituximab Restart

• Rituximab may be restarted at the full prescribed dose once the above criteria are met, even if the absolute neutrophil count remains < 500 cells/µL. 3
• Consider reducing the bendamustine dose (e.g., 50–70 mg/m² instead of the standard dose) after a serious infection, given its association with prolonged immunosuppression. 5

5. Bendamustine‑Rituximab (BR) Specific Risks and Prophylaxis

• The BR regimen is linked to higher rates of potentially fatal infections due to prolonged T‑cell suppression. 5
• The NCCN recommends that all patients receiving bendamustine‑rituximab be considered for PJP prophylaxis, not only those with a prior episode. 10
• Continue TMP/SMX secondary prophylaxis throughout all remaining BR cycles. 1
• Add broad antibacterial and antiviral prophylaxis during subsequent cycles because of the high infection risk associated with BR. 5
• If proteasome inhibitors are added later, herpes‑zoster prophylaxis may be warranted. 10

6. Monitoring After Therapy Restart

• Weekly complete blood counts should be performed to detect recurrent neutropenia. 3
• Maintain a high index of suspicion for breakthrough infections throughout the remainder of treatment. 5
• G‑CSF support can be considered in later cycles if severe neutropenia recurs, although it is not routine. 3

All statements are based on the cited literature; level of evidence was not explicitly stated in the source documents.